Objective. The aim of this study was to evaluate the cost effectiveness of a mobile-based intervention for patients with type 2 diabetes mellitus (T2DM) and compare it with the usual management mode. Method. A total of 215 patients with T2DM in a tertiary-care hospital specific to diabetes were selected as the study population. This study was conducted from January 1, 2019 to January 1, 2020. Of the 215 patients, 130 were randomly assigned to the mHealth group and 85 were assigned to the usual care group. IBM SPSS 25.0 software was used for descriptive statistics, t tests, chi-square tests, and correlation analyses. Haemoglobin A1c (HbA1c) was the effectiveness parameter adopted. Cost-effectiveness analyses were performed, and incremental cost-effectiveness ratios (ICERs) were calculated. Results. Of the 215 patients with T2DM, the proportion of male patients was 66.0%. The mean age of the patients was 47.2 (SD 9.95). Differences in baseline information were not statistically significant between the two groups (). At the 3-, 6-, and 12-month follow-ups, the mHealth group reported higher control rates of HbA1c than the usual care group, 67.9% versus 46.2% (), 72.4% versus 45.4% (), and 74.6% versus 47.1% (), respectively. The value of HbA1c was positively related to total patient cost, material fee, Western medicine fee, and hospitalization expenses (), with correlation coefficients of 0.202, 0.200, 0.172, and 0.183, respectively. The costs of the mHealth group and usual care group were CNY¥ 1169.76 and CNY¥ 1775.44 per patient/year, respectively. The incremental cost of the mHealth intervention was CNY¥ −605.68 per patient/year. The ICER was CNY¥ −22.02 per patient/year. Conclusion. Compared with the usual care mode, the mHealth management model for patients with T2DM improved the control rate of HbA1c, and the mHealth management mode had better cost effectiveness.

中文翻译：

---

2 型糖尿病患者基于移动设备的干预措施的成本效益分析

客观。本研究的目的是评估移动干预对 2 型糖尿病 (T2DM) 患者的成本效益，并将其与常规管理模式进行比较。方法。在一家专门针对糖尿病的三级医院中，共有 215 名 T2DM 患者被选为研究人群。该研究于 2019 年 1 月 1 日至 2020 年 1 月 1 日进行。在 215 名患者中，130 名被随机分配到移动医疗组，85 名被分配到常规护理组。IBM SPSS 25.0 软件用于描述性统计，t检验、卡方检验和相关分析。血红蛋白 A1c (HbA1c) 是采用的有效性参数。进行了成本效益分析，并计算了增量成本效益比 (ICER)。结果。215例T2DM患者中，男性患者比例为66.0%。患者的平均年龄为 47.2 岁（标准差 9.95）。两组基线信息差异无统计学意义（）。在 3 个月、6 个月和 12 个月的随访中，mHealth 组报告的 HbA1c 控制率高于常规护理组，分别为 67.9% 和 46.2%（), 72.4% 对 45.4% (), 74.6% 对 47.1% ()，分别。HbA1c 值与患者总费用、材料费、西药费、住院费呈正相关（)，相关系数分别为 0.202、0.200、0.172 和 0.183。mHealth 组和常规护理组的费用分别为每位患者/年 1169.76 元和 1775.44 元。移动医疗干预的增量成本为每位患者/年 -605.68 元人民币。ICER 为每名患者/年 CNY¥ -22.02。结论。与常规护理模式相比，T2DM患者的mHealth管理模式提高了HbA1c的控制率，mHealth管理模式具有更好的成本效益。